Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome

Oligometastatic (OMD) non-small cell lung cancer (NSCLC) is a distinct but heterogeneous entity. Current guidelines recommend systemic therapy and consolidation with local ablative therapy (LAT). However, evidence regarding the optimal choice of multimodal treatment approaches is lacking, in particular with respect to the integration of immunotherapy. This real-world study identified 218 patients with OMD NSCLC (2004-2023, prespecified criteria:

• Wiesweg, M.
• Küter, C.
• Schnorbach, J.
• Keyl, J.
• Metzenmacher, M.
• Cvetkovic, J.
• Saalfeld, F. C.
• Glanemann, F.
• Eberhardt, W.
• Oezkan, F.
• Theegarten, D.
• Stenzinger, A.
• Darwiche, K.
• Koschel, D.
• Herth, F.
• Bölükbas, S.
• Winter, H.
• Weykamp, F.
• Wermke, M.
• Stuschke, M.
• Plönes, T.
• Thomas, M.
• Schuler, M.
• Christopoulos, P.